The molecular mechanism of actinomycin D in preventing neointimal formation in rat carotid arteries after balloon injury

Journal of Biomedical Science

Volumn 12, Issue 3, 2005, Pages 503-512

  Wu, C H ^a   Pan, J S ^b   Chang, W C ^a   Hung, J S ^a   Mao, Simon J T ^b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

Actinomycin D; Neointimal formation; Proliferation; Restenosis

Indexed keywords

CYCLINE; DACTINOMYCIN; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAF PROTEIN;

ADVENTITIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA BALLOON; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; FLOW CYTOMETRY; GEL; IC 50; LD 50; MALE; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURGICAL INJURY; VASCULAR SMOOTH MUSCLE;

ANIMALS; BALLOON DILATATION; CAROTID ARTERIES; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; DACTINOMYCIN; LETHAL DOSE 50; MUSCLE, SMOOTH, VASCULAR; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; SIGNAL TRANSDUCTION; TUNICA INTIMA;

EID: 22744454963     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-005-6900-5     Document Type: Article

References (38)

1. J.M. Isner A. Pieczek R. Schainfeld R. Blair L. Haley T. Asahara K. Rosenfield S. Razvi K. Walsh J.F. Symes 1996 Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb Lancet 348 370 374
2. P.W. Serruys H.E. Luijten K.J. Beatt R. Geuskens P.J. de Feyter M. van den Brand J.H. Reiber H.J. ten Katen G.A. van Es P.G. Hugenholtz 1998 Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months Circulation 77 361 371
3. N.M. Mazure E.Y. Chen P. Yeh K.R. Laderoute A.J. Giaccia 1996 Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression Cancer Res. 56 3436 3440
4. H. Bult 2000 Restenosis: a challenge for pharmacology Trends Pharmacol. Sci. 21 274 279
5. M.R. Kibbe T.R. Billiar E. Tzeng 2000 Gene therapy for restenosis Circ. Res. 86 829 833
6. G. Jin J. Chieh-Hsi Wu Y.S. Li Y.L. Hu J.Y. Shyy S. Chien 2000 Effects of active and negative mutants of Ras on rat arterial neointima formation J. Surg. Res. 94 124 132
7. C.H. Wu C.S. Lin J.S. Hung C.J. Wu P.H. Lo G. Jin Y.J. Shyy S.J.T. Mao S. Chien 2001 Inhibition of balloon injury-induced neointimal formation in porcine coronary artery by an adenovirus-mediated ras mutant J. Surg. Res. 99 100 106
8. E. Grube U. Gerckens R. Muller L. Bullesfeld 2002 Drug eluting stents: initial experiences Z. Kardiol. 91 Suppl 3 44 48
9. R. Waksman 2002 Drug-eluting stents: from bench to bed Cardiovasc. Radiat. Med. 3 226 241
10. E. Regar G. Sianos P.W. Serruys 2001 Stent development and local drug delivery Br. Med. Bull. 59 227 248
11. J.W. Moses N. Kipshidze M.B. Leon 2002 Perspectives of drug-eluting stents: the next revolution Am. J. Cardiovasc. Drugs 2 163 172
12. P.W. Serruys J.A. Ormiston G. Sianos J.E. Sousa E. Grube P. den Heijer P. de Feyter P. Buszman A. Schomig J. Marco L. Polonski L. Thuesen A.M. Zeiher J.H. Bett M.J. Suttorp H.D. Glogar M. Pitney G.T. Wilkins R. Whitbourn S. Veldhof K. Miquel R. Johnson L. Coleman R. Virmani 2004 Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial J. Am. Coll. Cardiol. 44 1363 1367
13. T. Suzuki G. Kopia S. Hayashi L.R. Bailey G. Llanos R. Wilensky B.D. Klugherz G. Papandreou P. Narayan M.B. Leon A.C. Yeung F. Tio P.S. Tsao R. Falotico A.J. Carter 2001 Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model Circulation 104 1188 1193
14. A.W. Heldman L. Cheng G.M. Jenkins P.F. Heller D.W. Kim M. Ware Jr. C. Nater R.H. Hruban B. Rezai B.S. Abella K.E. Bunge J.L. Kinsella S.J. Sollott E.G. Lakatta J.A. Brinker W.L. Hunter J.P. Froehlich 2001 Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis Circulation 103 2289 2295
15. T.C. Chang L.C. Tsai M.W. Hung L.L. Chu J.T. Chu Y.C. Chen 1997 Effects of transcription and translation inhibitors on a human gastric carcinoma cell line. Potential role of Bcl-X(S) in apoptosis triggered by these inhibitors Biochem. Pharmacol. 53 969 977
16. K. Tamura Y.E. Chen M. Lopez-Ilasaca L. Daviet N. Tamura T. Ishigami M. Akishita I. Takasaki Y. Tokita R.E. Pratt M. Horiuchi V.J. Dzau S. Umemura 2000 Molecular mechanism of fibronectin gene activation by cyclic stretch in vascular smooth muscle cells J. Biol. Chem. 275 34619 34627
17. J.C. Schink D.K. Singh A.W. Rademaker D.S. Miller J.R. Lurain 1992 Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease Obstet. Gynecol. 80 817 820
18. M.H. Wu B.Y. Yung 1994 Cell cycle phase-dependent cytotoxicity of actinomycin D in HeLa cells Eur. J. Pharmacol. 270 203 212
19. H.K. Kim J.Y. Nam M.Y. Han E.K. Lee J.D. Choi S.H. Bok B.M. Kwon 1999 Actinomycin D as a novel SH2 domain ligand inhibits Shc/Grb2 interaction in B104-1-1 (neu*-transformed NIH3T3) and SAA (hEGFR-overexpressed NIH3T3) cells FEBS Lett. 453 174 178
20. Y. Lu Q. Yu J.H. Liu J. Zhang H. Wang D. Koul J.S. McMurray X. Fang W.K. Yung K.A. Siminovitch G.B. Mills 2003 Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades J. Biol. Chem. 278 40057 40066
21. C. Indolfi E.V. Avvedimento A. Rapacciuolo E. Di Lorenzo G. Esposito E. Stabile A. Feliciello E. Mele P. Giuliano G. Condorelli 1995 Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo Nat. Med. 1 541 555
22. L.E. Jeremy 1986 Stabilization and release effects of pluronic F127 in protein drug delivery J. Undergrad. Sci. 5 17 24
23. A.E. Villa L.A. Guzman E.J. Poptic V. Labhasetwar S. D'Souza C.L. Farrell E.F. Plow R.J. Levy P.E. DiCorleto E.J. Topol 1995 Effects of antisense c-myc oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury Circu. Res. 76 505 513
24. R.C.M. Siow C.M. Mallawaarachchi P.L. Weissberg 2003 Migration of adventitial myofibroblasts following vascular balloon injury: insights from in vivo gene transfer to rat carotid arteries Cardiovas. Res. 92 212 221
25. M. Ishikawa M. Akishita K. Kozaki K. Toba A. Namiki T. Yamaguchi H. Orimo Y. Ouchi 2000 Expression of parathyroid hormone-related protein in human and experimental atherosclerotic lesions: functional role in arterial intimal thickening Atherosclerosis 152 97 105
26. H.K. Kim J.Y. Nam M.Y. Han K.H. Son J.D. Choi B.M. Kwon H.L. Takusagawa Y. Huang F. Takusagawa 2000 Natural and synthetic analogues of actinomycin D as Grb2-SH2 domain blockers Bioorg. Med. Chem. Lett. 10 1455 1457
27. K. Matuoka M. Shibata A. Yamakawa T. Takenawa 1992 Cloning of ASH, a ubiquitous protein composed of one Src homology region (SH) 2 and two SH3 domains, from human and rat cDNA libraries Proc. Natl. Acad. Sci. USA 89 9015 9019
28. A. Aronheim D. Engelberg N. Li N. al-Alawi J. Schlessinger M. Karin 1994 Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the Ras signaling pathway Cell 78 949 961
29. J.H. Zhao H. Reiske J.L. Guan 1998 Regulation of the cell cycle by focal adhesion kinase J. Cell Biol. 143 1997 2008
30. A.H. Dorafshar N. Angle M. Bryer-Ash D. Huang M.M. Farooq H.A. Gelabert J.A. Freischlag 2003 Vascular endothelial growth factor inhibits mitogen-induced vascular smooth muscle cell proliferation J. Surg. Res. 114 179 186
31. G. Ghiselli J. Chen M. Kaou H. Hallak R. Rubin 2003 Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells Arterioscler. Thromb. Vasc. Biol. 23 1808 1813
32. D. Tang D. Wu A. Hirao J.M. Lahti L. Liu B. Mazza V.J. Kidd T.W. Mak A.J. Ingram 2002 ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53 J. Biol. Chem. 277 12710 12717
33. M.S. Colman C.A. Afshari J.C. Barrett 2000 Regulation of p53 stability and activity in response to genotoxic stress Mutat. Res. 462 179 188
34. T. Caspari 2002 How to activate p53 Curr. Biol. 10 R315 R317
35. N.T. Le D.R. Richardson 2003 Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation Carcinogen 24 6 1045 1058
36. D. Woods D. Parry H. Cherwinski E. Bosch E. Lees M. McMahon 1997 Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1 Mol. Cell Biol. 17 5598 5611
37. A. Sewing B. Wiseman A.C. Lloyd H. Land 1997 High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1 Mol. Cell Biol. 17 5588 5597
38. J.L. Duff B.P. Monia B.C. Berk 1995 Mitogen-activated protein (MAP) kinase is regulated by the MAP kinase phosphatase (MKP-1) in vascular smooth muscle cells. Effect of actinomycin D and antisense oligonucleotides J. Biol. Chem. 270 7161 7166